The company's pharmaceuticals division includes operations in both the radiopharmaceuticals and bioassays business segments. IBA's strategic business options were disclosed in the company's financial report for the first half of 2010 (end-June 30).
Revenues from sales and service increased slightly to 181.3 million euros ($230.2 million U.S.) in the first six months of 2010, compared with 180.8 million euros ($229.6 million U.S.) in the same period of 2009. The company's net profit, however, decreased to 2.6 million euros ($2.9 million U.S.) in the first half of 2010, compared with 3.2 million euros ($4.1 million U.S.) in the same period a year ago.
In its midyear financial statement, IBA noted that it plans to seek partners to meet market demand and keep funding its radiopharmaceuticals segment, which accounts for 60% of the company's sales.
"IBA could explore all the possibilities to reach this objective, without excluding an IPO of the activity, if the circumstances are adequate," the company stated.
Related Reading
IBA, Bayer ink imaging deal, August 27, 2010
IBA to build proton center in Poland, August 2, 2010
IBA wins Swedish contract, July 8, 2010
IBA inks deal with Procure, July 6, 2010
IBA, Wilex tout Redectane results, May 18, 2010
Copyright © 2010 AuntMinnie.com